Literature DB >> 35812568

Tacrolimus-Induced Diffuse Coronary Artery Spasm.

Abadil Samer1, Fahad Almehmadi1, Ahmed Krimly2, Abdullah Alrajhi3.   

Abstract

Prinzmetal angina, also known as vasospastic angina, is defined as an intermittent focal or diffuse coronary artery narrowing, which is often associated with transient ST-segment elevation on an electrocardiogram. Also, it could be associated with an atherosclerotic lesion at the site of the spasm. Vasospastic angina might be induced by medications, most commonly with cocaine and other examples which include catecholamines such as epinephrine, norepinephrine, isoproterenol, dopamine, and dobutamine. Parasympathomimetic agents include acetylcholine, methacholine, and pilocarpine. It is rarely caused by tacrolimus. The clinical evaluation includes an electrocardiogram and echocardiogram. The confirmed diagnosis is done by coronary angiography. Cardiac catheterization is indicated in such cases to rule out coronary artery disease.
Copyright © 2022, Samer et al.

Entities:  

Keywords:  coronary artery spasm; immunosuppressant; renal failure; solid organ transplant; tacrolimus

Year:  2022        PMID: 35812568      PMCID: PMC9270072          DOI: 10.7759/cureus.25748

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

Review 1.  Clinical determinants of calcineurin inhibitor disposition: a mechanistic review.

Authors:  Thomas Vanhove; Pieter Annaert; Dirk R J Kuypers
Journal:  Drug Metab Rev       Date:  2016-02-25       Impact factor: 4.518

Review 2.  Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

3.  Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina) (JCS 2013).

Authors: 
Journal:  Circ J       Date:  2014-09-30       Impact factor: 2.993

4.  Protein kinase CbetaII-mediated phosphorylation of endothelial nitric oxide synthase threonine 495 mediates the endothelial dysfunction induced by FK506 (tacrolimus).

Authors:  Valorie L Chiasson; Matthew A Quinn; Kristina J Young; Brett M Mitchell
Journal:  J Pharmacol Exp Ther       Date:  2011-03-07       Impact factor: 4.030

5.  Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm.

Authors:  Moisés Rodríguez-Mañero; Teresa Oloriz; Jean-Benoit le Polain de Waroux; Haran Burri; Bahij Kreidieh; Carlos de Asmundis; Miguel A Arias; Elena Arbelo; Brais Díaz Fernández; Juan Fernández-Armenta; Nuria Basterra; María Teresa Izquierdo; Ernesto Díaz-Infante; Gabriel Ballesteros; Andrés Carrillo López; Ignacio García-Bolao; Juan Benezet-Mazuecos; Victor Expósito-García; Jose Luis Martínez-Sande; Javier García-Seara; Jose Ramón González-Juanatey; Rafael Peinado
Journal:  Europace       Date:  2018-05-01       Impact factor: 5.214

Review 6.  The safety of calcineurin inhibitors for kidney-transplant patients.

Authors:  Paolo Malvezzi; Lionel Rostaing
Journal:  Expert Opin Drug Saf       Date:  2015-09-02       Impact factor: 4.250

7.  Tacrolimus nephrotoxicity: beware of the association of diarrhea, drug interaction and pharmacogenetics.

Authors:  Sandrine Leroy; Arnaud Isapof; Sonia Fargue; May Fakhoury; Albert Bensman; Georges Deschênes; Evelyne Jacqz-Aigrain; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2010-01-21       Impact factor: 3.714

Review 8.  Coronary artery spasm--clinical features, diagnosis, pathogenesis, and treatment.

Authors:  Hirofumi Yasue; Hitoshi Nakagawa; Teruhiko Itoh; Eisaku Harada; Yuji Mizuno
Journal:  J Cardiol       Date:  2008-02-01       Impact factor: 3.159

9.  Vasospastic Angina and Role of Cardiac Catheterization.

Authors:  Robert Kleyman; Rajiv Goyal; Neha Patel; Jessica Joseph; Rami Akel
Journal:  Cureus       Date:  2019-09-06

10.  Should ACE inhibitors or calcium channel blockers be used for post-transplant hypertension?

Authors:  Tomáš Seeman; Janusz Feber
Journal:  Pediatr Nephrol       Date:  2020-02-14       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.